# Impact of Nilotinib on Safety, Tolerability, Pharmacokinetics and Biomarkers in Parkinson's Disease

> **NCT02954978** · PHASE2 · UNKNOWN · sponsor: **Georgetown University** · enrollment: 75 (actual)

## Conditions studied

- Parkinson Disease
- Parkinsons Disease With Dementia

## Interventions

- **DRUG:** Placebo Oral Capsule
- **DRUG:** Nilotinib 150mg oral capsule [Tasigna]
- **DRUG:** Nilotinib 300mg oral capsule [Tasigna]

## Key facts

- **NCT ID:** NCT02954978
- **Lead sponsor:** Georgetown University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-01
- **Primary completion:** 2020-05
- **Final completion:** 2020-07
- **Target enrollment:** 75 (ACTUAL)
- **Last updated:** 2019-03-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02954978

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02954978, "Impact of Nilotinib on Safety, Tolerability, Pharmacokinetics and Biomarkers in Parkinson's Disease". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02954978. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*